CTA-091

CTA-091 is a synthetic vitamin D analogue designed as a dual-action ligand. It functions as an agonist of the Vitamin D receptor (VDR) and an antagonist of the cytochrome P450 enzyme CYP24A1 (24-hydroxylase). CYP24A1 is the primary enzyme responsible for the catabolism of active vitamin D (1,25-dihydroxyvitamin D3); by inhibiting this enzyme, CTA-091 is intended to prolong the half-life and therapeutic activity of both endogenous and exogenous vitamin D. The compound has been primarily utilized in preclinical research and computational molecular dynamics simulations to study its binding interactions and potential efficacy in treating pathogenesis related to chronic kidney disease (CKD). It was developed by Cytochroma, which was later acquired by OPKO Health.